Application of SRSF3 inhibitor in preparation of product for treating and / or preventing acute lymphocytic leukemia

Through artificial intelligence simulates the molecular docking model of drugs with SRSF3, SRSF3 inhibitors that can effectively inhibit ALL cell lines were screened from FDA-approved drugs, solving the problem of limited research on SRSF3 inhibitors in the prior art and providing a new clinical treatment option.

CN119700979AActive Publication Date: 2025-03-28THE SECOND XIANGYA HOSPITAL OF CENT SOUTH UNIV
2 Cites 0 Cited by

Patent Information

Application Number
CN202411904453.7
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2024-12-23
Publication Date
2025-03-28
Estimated Expiration
2044-12-23

AI Technical Summary

Technical Problem

Research on small molecule inhibitors targeting SRSF3 in the prior art is very limited, and the concentration of drugs used in existing studies is much higher than the physiological conditions in clinical treatment and cannot be directly applied to the clinic.

Method used

Based on the protein structure of SRSF3, artificial intelligence algorithms are used to simulate the molecular docking model of drugs and SRSF3, and drug molecules that are most likely to bind to SRSF3 are screened out from more than 2,000 drugs approved by the FDA, and the selected drugs are functionally verified through cellular experiments, and finally SRSF3 inhibitors can be used to treat and/or prevent acute lymphocytic leukemia.

Benefits of technology

Through artificial intelligence screening and cell experiment verification, SRSF3 inhibitors that can effectively inhibit cell viability, proliferation and clonal formation of ALL cell lines were obtained, providing more drug choices for clinical treatment of ALL.

✦ Generated by Eureka AI based on patent content.
Patent Text Reader

Abstract

The invention discloses an application of an SRSF3 inhibitor in preparation of a product for treating and / or preventing acute lymphocytic leukemia. Based on a protein structure of the SRSF3, an artificial intelligence algorithm is used for simulating a molecular docking model of a drug and the SRSF3, drug molecules most likely to be combined with the SRSF3 are screened from more than two thousand of drugs approved by FDA, functional verification is conducted on the screened drugs through cell experiments, and finally the SRSF3 inhibitor capable of being used for treating and / or preventing ALL is obtained.
Need to check novelty before this filing date? Find Prior Art